Company Overview and News
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company is developing mifepristone; a compound that modulates the effects of cortisol by acting as a competitive antagonist. As of January 2017, it had discovered three structurally distinct series of selective cortisol modulators.
Investors in Corcept Therapeutics, Inc. (CORT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $12.00 Put had some of the highest implied volatility of all equity options today.
2018-08-27 seekingalpha - 1
Insider buying declined sharply last week with insiders purchasing $43.43 million of stock compared to $200.17 million in the week prior. Selling on the other hand increased with insiders selling $1.95 billion of stock last week compared to $1.7 billion in the week prior.
2018-08-22 247wallst - 12
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports.
OCUL RIGL VYGR CORT LJPC ATNX SRPT
2018-08-11 zacks - 1
Corcept Therapeutics Inc. (CORT - Free Report) reported adjusted second-quarter 2018 earnings of 20 cents per share, missing the Zacks Consensus Estimate of 24 cents. However, the bottom line improved from the year-ago period’s figure of 13 cents on higher revenues.
GJV NWS NWSA CORT CELG ILMN PFE
2018-08-10 seekingalpha - 1
Good day and welcome to the Corcept Therapeutics Conference Call. Today’s conference is being recorded. [Operator Instructions]
Corcept Therapeutics (CORT - Free Report) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
PLNT GD CORT EPE
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Investors in Corcept Therapeutics Incorporated (CORT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $19.00 Put had some of the highest implied volatility of all equity options today.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
2018-06-25 fintel.io - 11
PAVmed Inc. (OTC:PAVMU) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,174,480 shares. Largest shareholders include Sabby Management, LLC, Levin Capital Strategies, L.p., Vanguard Group Inc, Levin Capital Strategies, L.p., Moloney Securities Asset Management, LLC, Susquehanna International Group, Llp, Morgan Stanley, Brown Advisory Inc, UBS Group AG, and Fifth Third Bancorp.
PAVMU CORT PAVMW FITBI UBS PAVM FITB MS ULSGF
KonaTel, Inc. (OTC:KTEL) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . KonaTel, Inc. (OTC:KTEL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
2018-06-25 - Asif
Overview Corcept Therapeutics is engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Elevated levels and abnormal release patterns of cortisol are implicated in a broad range of diseases. The company's first approved product, Korlym®, treats patients with Cushing’s syndrome, a rare disease that is caused by excess cortisol activity. The active ingredient in Korlym is mifepristone, a compound that modulates cortisol activity by acting as a competitive antagonist at the glucocorticoid receptor (“GR”), one of the body’s two cortisol receptors. The company first made Korlym available to patients commercially in April 2012. Corcept Therapeutics has discovered three structurally distinct series of proprietary, selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone re...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to CORT / Corcept Therapeutics, Inc. on message board site Silicon Investor.
as of ET